INCAGN02390
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for INCAGN02390, covering 2025-10-03 to 2026-08-17. Get the full timeline:
Most recent: Clinical Trial Results: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies [Phase 1, Phase 2]